Blood cancer treatment trial succeeds

Israel’s Gamida Cell (reported here previously) published the results of its Phase 3 trial of omidubicel (previously NiCord) in blood-based cancer patients. The treatment resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the hospital.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *